Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2012 | 05:26am CEST
   By Rumman Ahmed 
 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
Stocks mentioned in the article
ChangeLast1st jan.
BIOCON LTD -1.94% 608 End-of-day quote.15.43%
BRISTOL-MYERS SQUIBB COMPANY -0.02% 53.64 Delayed Quote.-10.57%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
06/19THE GLOBAL ORGAN PRESERVATION MARKET : Some of the key players in Global Organ P..
AQ
06/18BRISTOL MYERS SQUIBB : BMS scores China's first IO approval
AQ
06/17BRISTOL MYERS SQUIBB : Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dex..
BU
06/15BRISTOL MYERS SQUIBB : China National Drug Administration Approves Country&rsquo..
BU
06/15BRISTOL MYERS SQUIBB : to Present New Research Findings on the Treatment of Pati..
AQ
06/14BRISTOL MYERS SQUIBB : Trademark Application for "OBREFCO" Filed by Bristol-Myer..
AQ
06/14BRISTOL MYERS SQUIBB : Patent Issued for Radioligands for Imaging the LPA-1 Rece..
AQ
06/14REPORTS OUTLINE LUNG CANCER STUDY RE : Quantitative analysis of specific potenti..
AQ
06/14STUDIES FROM BRISTOL-MYERS SQUIBB YI : ...
AQ
06/14BRISTOL MYERS SQUIBB : Opdivo Plus Chemotherapy Showed Improved Progression-Free..
AQ
More news
News from SeekingAlpha
06/19Idera Stock Has Declined Since Failure Of Phase 2 Trial In Rare Disease, But .. 
06/18Bristol-Myers Squibb's Empliciti reduced risk of cancer progression in mid-st.. 
06/17WEEK IN REVIEW : Mevion Medical Of Boston Closes $150 Million Financing From Chi.. 
06/173 THINGS IN BIOTECH, JUNE 16 : Do You Know Anything About EHA? 
06/14Bristol-Myers Squibb declares $0.40 dividend 
Financials ($)
Sales 2018 21 740 M
EBIT 2018 5 499 M
Net income 2018 4 486 M
Finance 2018 428 M
Yield 2018 3,04%
P/E ratio 2018 18,95
P/E ratio 2019 16,13
EV / Sales 2018 4,01x
EV / Sales 2019 3,70x
Capitalization 87 693 M
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 57,3 $
Spread / Average Target 6,9%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-10.57%89 573
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 330
ROCHE HOLDING LTD.-14.81%184 168
MERCK AND COMPANY8.39%166 880